Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors

NEW YORK–(BUSINESS WIRE)– Regulatory News:

Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a
clinical-stage biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART), today
announced that it has appointed Rainer Boehm, M.D. and Hervé Hoppenot to
its Board of Directors.

“We are delighted to welcome Rainer Boehm and Hervé Hoppenot to our
Board. Rainer’s experience in drug commercialization will be invaluable
as we work to develop the next generation CAR T-cell immunotherapies.
Hervé brings deep expertise in oncology which will be a major benefit to
our team we continue to innovate to bring UCART product candidates to
the clinic,” said André Choulika, CEO Cellectis. “With these two
esteemed leaders, we are adding to the expertise of our Board of
Directors to help guide Cellectis into our next phase.”

Rainer Boehm spent 29 years at Novartis, working locally, regionally and
globally in various Senior Management roles, after building his career
in Marketing & Sales and Medical Affairs. He led all emerging markets
regions as well as the United States and Canada, either for Oncology or
the Pharmaceuticals division. His most recent assignments were Chief
Commercial and Medical Affairs Officer globally for Novartis Pharma, as
well as ad interim CEO and Division Head Pharma. Rainer launched and
oversaw the commercialization of many brands during his career, amongst
them Femara, Zometa and Glivec, as well as Cosentyx and Entresto. His
broad interests include leadership development, coaching and mentoring,
access to medicines and new business models including solutions to
leverage digital medicines and real world evidence. Rainer has a medical
degree from the University of Ulm in Germany, and a Master of Business
Administration from Schiller University in France.

“I am honored to join the Board and look forward to providing strategic
advice on drug commercialization to strengthen Cellectis’ market leading
position. Cellectis is a company with tremendous potential,” said Rainer
Boehm, Cellectis’ newest Board member. “I see exciting opportunities for
Cellectis to address unmet medical needs and make a meaningful
difference in people’s lives. What Cellectis is accomplishing is
transformative and we have the potential to move the needle forward for
healthcare in a positive way.”

Hervé Hoppenot joined Incyte Corporation in 2014 as President and Chief
Executive Officer, and was appointed Chairman of the Board of Directors
in 2015. Incyte is one of the fastest growing biopharmaceutical
companies in the U.S. Incyte’s team of more than 1,000 scientists,
clinicians, and other team members operating in 15 countries, strives to
discover and develop first-in-class and best-in-class medicines for
cancer and other diseases. The Company is advancing a diverse portfolio
of large and small molecules comprised of 18 development candidates
against 14 different molecular targets and in 2016 Incyte reported
revenue of more than $1 billion.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis
Oncology, which included $11 billion in global sales, the largest
oncology pipeline in the industry and 8000 employees in 50 countries.
Prior to joining Novartis in 2003, Mr. Hoppenot started his career in
1983 with Rhone Poulenc, later known as Aventis, where he served in
several senior roles of increasing responsibility, including Vice
President of Oncology and Head of the US Oncology business unit. He and
his family are dual citizens of France and the United States, having
moved to the U.S. in 1991.

« Despite many advances in oncology, there remains a need to continue to
advance the science to meet the needs of patients. Through its work in
developing CAR T immunotherapies, Cellectis has an opportunity to make a
significant contribution to the treatment of cancer,” Mr. Hoppenot said.
« I am excited to be joining the Cellectis Board during this important
time of growth. »

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing – built on its flagship TALEN® technology and
pioneering electroporation system PulseAgile – Cellectis uses the power
of the immune system to target and eradicate cancer cells. Using its
life-science-focused, pioneering genome engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170628006216/en/